Imperial College London
Portrait Picture

ProfessorNicholaCooper

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Immune Haematology
 
 
 
//

Contact

 

n.cooper

 
 
//

Assistant

 

Miss Mandy Sale +44 (0)20 3313 4017

 
//

Location

 

4S10CCommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cooper:2019:10.1097/01.hs9.0000561120.77547.ad,
author = {Cooper, N and Bird, R and Hato, T and Kuter, D and Lozano, M and Michel, M and Platzbecker, U and Provan, D and Scheinberg, P and Tomiyama, Y and Wong, R and Bussel, JB},
doi = {10.1097/01.hs9.0000561120.77547.ad},
journal = {HemaSphere},
pages = {309--310},
title = {PF709 TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS},
url = {http://dx.doi.org/10.1097/01.hs9.0000561120.77547.ad},
volume = {3},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:sec><jats:title>Background:</jats:title><jats:p>Immune thrombocytopenia (ITP) is an acquired autoimmunemediated disorder characterized by a platelet count <100,000/μL and variable bleeding and fatigue. Firstline treatment is usually corticosteroids, which provide high response rates but are only recommended for shortterm use, due to toxicities associated with longterm use. Thrombopoietin receptor agonists (TPORAs), romiplostim and eltrombopag, are secondline treatments that stimulate platelet production. Initially, it was thought that once a TPORA was started, treatment would continue indefinitely. However, it became clear that certain patients can discontinue TPORAs and maintain adequate platelet counts after stopping treatment. However, there is no clarity on how many and which patients might achieve sustained responses off treatment and which strategies are optimal to achieve these responses.</jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p>To develop an expert physicianled strategy for discontinuing TPORA treatment in ITP patients.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Twelve experts from the US, Brazil, Western Europe, Asia, and Australia responded to a specially designed questionnaire focusing on: selection of patients for tapering and discontinuation of TPORA agents, optimal strategy to do so, monitoring approaches during and after discontinuation, and when and how to reinstate treatment if there was a relapse.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The respondents agreed that patients with persistent or chronic ITP receiving any dose of TPORA could be considered for dose reduction in cases of stable response to treatment. Other factors should be considered, including a prior bleeding episode due to platelet count drop, ha
AU  - Cooper,N
AU  - Bird,R
AU  - Hato,T
AU  - Kuter,D
AU  - Lozano,M
AU  - Michel,M
AU  - Platzbecker,U
AU  - Provan,D
AU  - Scheinberg,P
AU  - Tomiyama,Y
AU  - Wong,R
AU  - Bussel,JB
DO  - 10.1097/01.hs9.0000561120.77547.ad
EP  - 310
PY  - 2019///
SN  - 2572-9241
SP  - 309
TI  - PF709 TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS
T2  - HemaSphere
UR  - http://dx.doi.org/10.1097/01.hs9.0000561120.77547.ad
VL  - 3
ER  -
Download